Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions - GBI Research Reports

Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions

Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions - GBI Research Reports
Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
Published Dec 22, 2010
198 pages — Published Dec 22, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest report, 'Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions' that provides key data, information and analysis of the major trends and issues affecting the biotech industry. The report provides a comprehensive insight into the biotech industry 2009-2010. The report also provides a detailed analysis of biotech industry market characterization in terms of its market size, segmentation and the major market drivers and barriers. The report also talks about the patent landscape for biotech industry and provides comprehensive analysis. The report also looks into the biotech industry product pipeline along with analysis on the pipeline by indication, phase of development and geography of development. The report also provides competitive landscape of the market that profiles key market players along with their brief business description, pipeline, major products and major M&A and partnership deals.

Scope

The scope of the report includes:
- Detailed overview of biotech industry in 2009-2010
- Key market drivers and restraints,challenges and restraints shaping the biotech industry market
- Pipeline analysis of the biotech industry along with segmentation by indication, phase and geography
- Competitive landscape analysis with competitive profiling of leading companies
- Analysis of M&A deals 2009-2010 along with segmentation by value geography and companies

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Develop better strategies for biotech industry by understanding the market dynamics of the biotech industry
- Develop market-entry and market expansion strategies by identifying the key areas for high growth and high opportunities
- Understand the factors shaping the biotech industry market
- Identify the key players best positioned to take the advantage of the opportunities in the global biotech industry market
- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps

  
Source:
Document ID
GBIHC047MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents38
List of Tables72
List of Figures92
Introduction112
GBI Research Report Guidance121
Market Characterization1313
Total Revenues for Biologics Sales in 2009134
Drivers and Restraints171
Innovation Gap in Pharmaceutical R&D: Bigger Pharmaceutical Companies are Looking at Biotechnology Innovations to Fill the Gap in Pharmaceutical R&D181
Patent Expiries of Pharmaceutical Blockbusters: Pharmaceutical Companies are Focusing on Biologics due to Lack of Patent Expiry in Recent Years181
Huge Investments in Biotechnology R&D Resulting in Strong Product Pipeline181
Higher Approval Rates for Biotech Products have contributed to Growth of Biotechnology Industry191
High Unmet Needs in Life Threatening Diseases are driving the Biotechnology Market191
Increasing Interest of Pharmaceutical Companies in Biotechnology Industry will Aid the Growth of the Biotechnology Industries191
Strong Growth of Biologics in the Market for Cancer and Autoimmune Diseases191
Restraints201
High Treatment Costs and Low Patient Compliance for Biologics are Slowing down the Market201
Threat from Biosimilars211
Lengthy Approval Process Reduces the Product s Effective Period of Commercial Success211
Trends221
Development of the Monoclonal Antibodies: Many Biotech Industries are eyeing on Monoclonal Antibodies as High Profit Products221
Biologics for Rheumatoid Arthritis and Cancer: Rheumatoid Arthritis and Cancer are Promising Therapeutic Areas for Biologics231
Biologics for Rheumatoid Arthritis231
Biologics for Cancer241
Challenges241
Challenges in the Biologics Development241
Resources: Lack of Funding Resources has created a Big Challenge for the Biotech Industries251
Compliance Challenge: Complex Regulation and Competition from Biosimilars is Slowing Down the Biotech Market251
Global Biosimilars Market2614
Global Market Size and Forecasts261
The US Biosimilars Market Size and Forecasts261
Europe Biosimilars Market Size and Forecasts271
Japan Biosimilars Size and Market Forecasts281
Market Forecasts for Biosimilars291
Human Growth Hormone Biosimilars Markets292
Erythropoietin Biosimilars Markets311
Granulocyte-Colony Stimulating Factor Biosimilars Markets322
Opportunity Analysis341
Interferon-alpha Biosimilars341
Interferon-Beta Biosimilars352
Insulin and Insulin Analogs Biosimilars372
Monoclonal Antibodies391
Therapeutic Landscape4014
Total Biologics Revenue by Drug Classes401
Cancer Antibodies411
Top Selling Products in Cancer Antibodies 2009411
TNF Alpha Antagonist421
Top Selling Products in TNF Antagonist Biologics 2009421
Insulin Products431
Top Selling Insulin Products - 2009431
Erythropoiesis Stimulating Agents441
Top Selling Products in Erythropoiesis Stimulating Agents 2009441
Interferon Alpha and Interferon Beta451
Top Selling Products in Interferon-Alpha - 2009451
Top Selling Products in Interferon-Beta - 2009451
Coagulation Factors461
Top Selling Products in Coagulation Factors 2009461
Granulocyte-Colony Stimulating Factor471
Top Selling Products in Granulocytes-Colony Stimulating Factors 2009471
Anti-Inflammatory Antibodies481
Top Selling Products in Anti-Inflammatory Antibodies 2009481
Human Growth Hormone491
Top Selling Products in Human Growth Hormone 2009491
Enzyme Replacement Therapy501
Top Selling Products in Enzyme Replacement Therapy 2009501
Follicle Stimulating Hormone511
Top Selling Products in Follicle Stimulating Hormone Products - 2009511
Antibody Products511
Top Selling Products in Antibodies 2009511
Proteins &Peptides521
Top Selling Products in Therapeutic Proteins 2009521
Top Selling Products in Peptides 2009531
Top 10 Biotechnology Companies5498
Roche/Genentech541
Company Overview541
Business Description541
Revenues from Biologics551
Drugs in Pipeline561
Roche Phase I Product Pipeline561
Roche. .Phase II Product Pipeline571
Roche Phase III Product Pipeline573
Merger &Acquisitions Deals601
Financials611
Ratio Analysis621
Profitability Ratios621
Efficiency Ratios621
SWOT Analysis631
Strengths631
Weakness641
Opportunities651
Threats661
Amgen Inc.671
Company Overview671
Business Description671
Revenues of Biologics681
Drugs in Pipeline691
Amgen Inc. Phase I Product Pipeline691
Amgen Inc. Phase II Product Pipeline701
Amgen Inc. Phase III Product Pipeline711
Merger and Acquisition Deals721
Financials731
Ratio Analysis741
Profitability Ratios741
Efficiency Ratios741
SWOT Analysis751
Strengths751
Weaknesses761
Opportunities761
Threats761
Novo Nordisk A/S771
Company Overview771
Business Description771
Revenues from Biologicals771
Biopharmaceuticals771
Product Wise Revenue783
Drugs in the Pipeline811
Novo Nordisk Phase I Product Pipeline811
Novo Nordisk Phase II Product Pipeline811
Novo Nordisk Phase III Product Pipeline821
Merger and Acquisition Deals831
Financials831
Ratio Analysis841
Profitability Ratios841
Efficiency Ratios841
SWOT Analysis851
Strengths851
Weaknesses861
Opportunuities861
Threats861
Merck Serono S.A (Merck Serono)871
Company Overview871
Business Overview871
Revenues from Biological882
Drugs in Pipeline901
Merck Serono Phase I Product Pipeline901
Merck Serono Phase II Product Pipeline901
Merck Serono Phase III Product Pipeline912
Merger and Acquisition Deals931
Financials933
Ratio Analysis961
Profitability Ratios961
Efficiency Ratios961
SWOT Analysis971
Strengths971
Weaknesses971
Opportunities981
Threats981
Baxter International Inc991
Company Overview991
Business Overview991
Revenues from Biologics1001
Product Wise Revenue1011
Drugs in Pipeline1021
Baxter Bioscience Phase I Product Pipeline1021
Baxter Bioscience Phase II Product Pipeline1021
Baxter Bioscience Phase III Product Pipeline1021
Merger &Acquisition Deals1031
Financials1031
Ratio Analysis1041
Profitability Ratios1041
Efficiency Ratios1051
SWOT Analysis1051
Strengths1061
Weaknesses1061
Opportunities1071
Threats1071
Biogen Idec Inc.1081
Company Overview1081
Business Description1081
Product Wise Revenue1091
Drugs in Pipeline1101
Biogen Idec Inc. Phase I Product Pipeline1101
Biogen Idec Inc. Phase II Product Pipeline1101
Biogen Idec Inc. Phase III Product Pipeline1111
Merger &Acquisition Deals1121
Financials1121
Ratio Analysis1131
Profitability Ratios1131
Efficiency Ratios1131
SWOT Analysis1141
Strengths1141
Weaknesses1151
Opportunities1151
Threats1151
Genzyme Corporation1161
Company Overview1161
Business Description1161
Product Wise Revenue1163
Drugs in Pipeline1191
Genzyme - Phase I Product Pipeline1191
Genzyme - Phase II Product Pipeline1191
Genzyme - Phase III Product Pipeline1201
Merger &Acquisition Deals1211
Financials1212
Ratio Analysis1231
Profitability Ratios1231
Efficiency Ratios1231
SWOT Analysis1241
Strengths1241
Weaknesses1251
Opportunities1251
Threats1251
CSL Limited1261
Introduction1261
Business Description1261
Revenues from Biologics1271
Drugs in Pipeline1281
CSL Ltd. Phase I Product Pipeline1281
CSL Ltd. Phase II Product Pipeline1281
CSL Ltd. Phase III Product Pipeline1281
Merger &Acquisition Deals1291
Financials1301
Ratio Analysis1311
Profitability Ratios1311
Efficiency Ratios1311
SWOT Analysis1321
Strength1321
Weakness1331
Opportunities1331
Threats1331
Allergan Inc.1341
Companies Overview1341
Business Description1341
Revenue from Biologics1341
Product Wise Revenue1343
Drugs in Pipeline1371
Allergan Inc. Phase I Product Pipeline1371
Allergan Inc. Phase II Product Pipeline.1371
Allergan Inc. Phase III Product Pipeline1381
Merger &Acquisition Deals1381
Financials1391
Ratio Analysis1401
Profitability Ratios1401
Efficiency Ratios1401
SWOT Analysis1411
Strengths1411
Weaknesses1421
Opportunities1421
Threats1431
Alexion Pharmaceutical Inc1441
Companies Overview1441
Business Overview1441
Revenues from Biological1451
Product Pipeline1451
Alexion Pharmaceutical Inc. Phase I Product Pipeline1461
Alexion Pharmaceutical Inc. Phase II Product Pipeline1461
Alexion Pharmaceutical Inc. Phase III Product Pipeline1471
Merger &Acquisition Deals1471
Financials1471
Ratio Analysis1481

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions" Dec 22, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Biotechnology-Industry-2010-Yearbook-Top-Biologics-Biosimilars-Licensing-and-Financing-Mergers-and-Acquisitions-2115-123>
  
APA:
GBI Research Reports. (2010). Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions Dec 22, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Biotechnology-Industry-2010-Yearbook-Top-Biologics-Biosimilars-Licensing-and-Financing-Mergers-and-Acquisitions-2115-123>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.